mantle cell lymphoma

Summary

Summary: A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).

Top Publications

  1. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408-18 pubmed publisher
    b>Mantle cell lymphoma (MCL) is typically a very aggressive disease with poor outcomes, but some cases display an indolent behavior that might not necessitate treatment at diagnosis...
  2. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis G, Medeiros L. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol. 2006;169:2171-80 pubmed
    b>Mantle cell lymphoma (MCL) is characterized by the t(11;14) and cyclin D1 overexpression. However, additional molecular events are most likely required for oncogenesis, possibly through cell cycle and apoptosis deregulation...
  3. Coiffier B, Ribrag V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk Lymphoma. 2009;50:1916-30 pubmed publisher
    ..b>Mantle cell lymphoma (MCL) was the first hematologic malignancy in which mTOR inhibition was explored as a treatment strategy, ..
  4. Weinkauf M, Zimmermann Y, Hartmann E, Rosenwald A, Rieken M, Pastore A, et al. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis. 2009;30:974-86 pubmed publisher
    ..Using 2-D PAGE in five mantle cell lymphoma cell lines, we screened for cellular protein level alterations following treatment with 25 nM bortezomib ..
  5. Baseggio L, Traverse Glehen A, Petinataud F, Callet Bauchu E, Berger F, Ffrench M, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica. 2010;95:604-12 pubmed publisher
    ..Whether or not CD5-positive splenic marginal zone B-cell lymphoma constitutes a true subset obviously requires the study of more cases. ..
  6. Garcia M, Romaguera J, Inamdar K, Rassidakis G, Medeiros L. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytar. Cancer. 2009;115:1041-8 pubmed publisher
    It has been demonstrated that the tumor proliferation index has prognostic significance in patients with mantle cell lymphoma (MCL). Patients in most of studies, however, have been treated with relatively traditional chemotherapy regimens...
  7. Nishimura H, Akiyama T, Monobe Y, Matsubara K, Igarashi Y, Abe M, et al. Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma. Mod Pathol. 2010;23:439-49 pubmed publisher
    ..malignancy cases demonstrated that sphingosine-1-phosphate receptor 1 was expressed on the surface of mantle cell lymphoma cells...
  8. Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385-7 pubmed
    Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous...
  9. Hartmann E, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116:953-61 pubmed publisher
    The genome of mantle cell lymphoma (MCL) is, in addition to the translocation t(11;14), characterized by a high number of secondary chromosomal gains and losses that probably account for the various survival times of MCL patients...

More Information

Publications93

  1. Rizzatti E, Mora Jensen H, Weniger M, Gibellini F, Lee E, Daibata M, et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma. 2008;49:798-808 pubmed publisher
    Bortezomib is more active against mantle cell lymphoma (MCL) than against most other lymphoma subtypes. Nevertheless, up to half of patients with MCL have bortezomib resistant disease...
  2. Zanetto U, Dong H, Huang Y, Zhang K, Narbaitz M, Sapia S, et al. Mantle cell lymphoma with aberrant expression of CD10. Histopathology. 2008;53:20-9 pubmed publisher
    ..Expression of CD10 by MCL is often associated with other variant morphological, immunophenotypic or genetic features, but does not reflect derivation from germinal centre B cells. ..
  3. Dictor M, Ek S, Sundberg M, Warenholt J, György C, Sernbo S, et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica. 2009;94:1563-8 pubmed publisher
    We surveyed lymphomas to determine the range of expression of the mantle cell lymphoma-associated SOX11 transcription factor and its relation to cyclin D1...
  4. Liu H, Huang J, Wang J, Jiang S, Bailey A, Goldman D, et al. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma. J Exp Med. 2008;205:1843-58 pubmed publisher
    In mantle cell lymphoma (MCL) and some cases of multiple myeloma (MM), cyclin D1 expression is deregulated by chromosome translocations involving the immunoglobulin heavy chain (IgH) locus...
  5. Reddy K, Ansari Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk Lymphoma. 2008;49:740-50 pubmed publisher
    MYC gene rearrangements are observed as a genetic change in the blastoid variant of mantle cell lymphoma (MCL)...
  6. Rodriguez Justo M, Huang Y, Ye H, Liu H, Chuang S, Munson P, et al. Cyclin D1-positive diffuse large B-cell lymphoma. Histopathology. 2008;52:900-3 pubmed publisher
  7. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Van Hoof A, Kluin Nelemans H, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-65 pubmed
    There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for ..
  8. Di Lisio L, Gomez Lopez G, Sanchez Beato M, Gomez Abad C, Rodriguez M, Villuendas R, et al. Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia. 2010;24:1335-42 pubmed publisher
    b>Mantle cell lymphoma (MCL) pathogenesis is still partially unexplained...
  9. Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai S, et al. A clinicopathologic study of mantle cell lymphoma in a single center study in India. Indian J Pathol Microbiol. 2008;51:315-22 pubmed
    We present clinical features, histopathology and results of treatment in cases of mantle cell lymphoma (MCL) at our hospital. We had 93 cases (2.1%) of MCL out of total 4301 cases of non-Hodgkin's lymphoma (NHL) in a 4-year period...
  10. Pal S, Baiocchi R, Byrd J, Grever M, Jacob S, SIF S. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J. 2007;26:3558-69 pubmed
    ..PRMT5 expression in normal human B lymphocytes and a panel of lymphoid cancer cell lines as well as mantle cell lymphoma (MCL) clinical samples...
  11. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol. 2008;19:135-41 pubmed
    Extranodal involvement, including central nervous system (CNS), is a frequent event in patients with mantle cell lymphoma (MCL). However, the incidence, risk factors, and impact on outcome remain controversial...
  12. Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann E, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 2009;113:3059-69 pubmed publisher
    b>Mantle cell lymphoma (MCL) is genetically characterized by the t(11;14)(q13;q32) translocation and a high number of secondary chromosomal alterations. However, only a limited number of target genes have been identified...
  13. Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett J, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553-9 pubmed publisher
    ..induction of apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC) with clinical efficacy in mantle cell lymphoma (MCL). Lenalidomide (LEN), a novel immunomodulatory agent, sensitizes tumor cells and enhances ADCC...
  14. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299:161-70 pubmed publisher
    ..synergistic growth-inhibitory effect of an MDM2 inhibitor Nutlin-3 and a proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) cells regardless of TP53 mutant status and innate bortezomib sensitivity...
  15. Herens C, Lambert F, Quintanilla Martinez L, Bisig B, Deusings C, de Leval L. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood. 2008;111:1745-6 pubmed publisher
  16. Kurtova A, Tamayo A, Ford R, Burger J. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113:4604-13 pubmed publisher
    b>Mantle cell lymphoma (MCL) is characterized by an early, widespread dissemination and residual disease after conventional treatment, but the mechanisms responsible for lymphoma cell motility and drug resistance are largely unknown...
  17. Hsi E, Jung S, Lai R, Johnson J, Cook J, Jones D, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008;49:2081-90 pubmed publisher
    The proliferation index in mantle cell lymphoma (MCL) has not been validated in the context of aggressive therapy regimens in the rituximab era...
  18. Murga Penas E, Callet Bauchu E, Ye H, Gazzo S, Berger F, Schilling G, et al. The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma. Blood. 2010;115:2214-9 pubmed publisher
    ..Furthermore, analogous to follicular and mantle cell lymphoma, templated nucleotides (T-nucleotides) were identified at the t(14;18)/IGH-MALT1 breakpoint junctions...
  19. Rolland D, Raharijaona M, Barbarat A, Houlgatte R, Thieblemont C. Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer Res. 2010;30:3951-7 pubmed
    b>Mantle cell lymphoma (MCL) is a chemoresistant lymphoma overexpressing the class pi glutathione-S-transferase (GST-pi). The nuclear localisation of GST-pi is induced by chemotherapy and is correlated to cell resistance...
  20. Hogan C, Hutchison C, Marcar L, Milne D, Saville M, Goodlad J, et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem. 2008;283:18012-23 pubmed publisher
  21. Wang X, Asplund A, Porwit A, Flygare J, Smith C, Christensson B, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol. 2008;143:248-52 pubmed publisher
    Gene expression analysis demonstrated high expression of the neuronal transcription factor SOX11 in mantle cell lymphoma (MCL)...
  22. Ruan J, Martin P, Coleman M, Furman R, Cheung K, Faye A, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655-64 pubmed publisher
    ..authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).
  23. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A, et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood. 2008;111:5142-51 pubmed publisher
    Functional characterization of signaling pathways that critically control mantle cell lymphoma (MCL) cell growth and survival is relevant to designing new therapies for this lymphoma...
  24. Tucker C, Kapanen A, Chikh G, Hoffman B, Kyle A, Wilson I, et al. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther. 2008;7:749-58 pubmed publisher
    ..In this study, we investigated the cell signaling pathways activated in bcl-2-overexpressing human mantle cell lymphoma cell lines (JVM-2 and Z-138) that have been treated with oblimersen, a molecular gene silencing strategy ..
  25. Estrozi B, Sanches J, Varela P, Bacchi C. Primary cutaneous blastoid mantle cell lymphoma-case report. Am J Dermatopathol. 2009;31:398-400 pubmed publisher
    b>Mantle cell lymphoma (MCL) commonly involves extranodal sites, usually as a manifestation of disseminated disease. In rare cases, MCLs may arise as a primary tumor in the skin...
  26. Goy A, Bernstein S, Kahl B, Djulbegovic B, Robertson M, De Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520-5 pubmed publisher
    We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL).
  27. Paoluzzi L, Scotto L, Marchi E, Seshan V, O Connor O. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol. 2009;146:656-9 pubmed publisher
    ..b>Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by overexpression of cyclin-D1...
  28. Farfsing A, Engel F, Seiffert M, Hartmann E, Ott G, Rosenwald A, et al. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia. 2009;23:2018-26 pubmed publisher
    The two B-cell non-Hodgkin's lymphoma entities, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), show recurrent chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22...
  29. Alinari L, White V, Earl C, Ryan T, Johnston J, Dalton J, et al. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009;1:31-40 pubmed
    b>Mantle cell lymphoma (MCL) is a distinct histologic subtype of B cell non-Hodgkins lymphoma (NHL) associated with an aggressive clinical course...
  30. Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B. Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer. 2006;6:238 pubmed
    ..of cyclin D1b mRNA and protein has been studied in two hemopathies in which cyclin D1 could be present: multiple myeloma (MM) and mantle cell lymphoma (MCL). The A/G polymorphism of CCND1 has also been verified in a series of patients.
  31. Zapata M, Budnick S, Bordoni R, Li S. An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. Int J Clin Exp Pathol. 2010;3:430-6 pubmed
    b>Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by expression of CD5, overexpression of Cyclin D1 as a result of chromosomal translocation t(11;14)(q13;q32), and poor prognosis...
  32. Rinaldi A, Poretti G, Kwee I, Zucca E, Catapano C, Tibiletti M, et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma. 2007;48:410-2 pubmed
  33. Fisher R, Bernstein S, Kahl B, Djulbegovic B, Robertson M, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867-74 pubmed
    Evaluate response rate, duration of response (DOR), time-to-progression (TTP), overall survival (OS), and safety of bortezomib treatment in patients with relapsed or refractory mantle cell lymphoma (MCL).
  34. Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-306 pubmed
    ..and rituximab (BMR) in patients with stage III/IV relapsed or refractory indolent lymphomas and mantle cell lymphoma (MCL) with or without prior rituximab containing chemo-immunotherapy (R-chemo) treatment...
  35. Wang M, Oki Y, Pro B, Romaguera J, Rodriguez M, Samaniego F, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:5213-8 pubmed publisher
    This phase II trial evaluated the safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (MCL).
  36. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies Hill T, Miyake K, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15:933-42 pubmed publisher
    b>Mantle cell lymphoma (MCL) has one of the poorest prognoses of the non-Hodgkin's lymphomas, and novel therapeutic approaches are needed...
  37. Li Y, Williams M, Cousar J, Pawluczkowycz A, Lindorfer M, Taylor R. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol. 2007;179:4263-71 pubmed
    ..Z138 cells, a B cell line derived from human mantle cell lymphoma, were infused i.v. or s.c. The i.v...
  38. Garcia Munoz R, Panizo C, Bendandi M, Llorente L. Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?. Leuk Res. 2009;33:1437-9 pubmed publisher
    b>Mantle cell lymphoma (MCL) is an aggressive B cell malignancy, which is believed to originate from naïve B cells in the mantle zone of lymph nodes...
  39. Schraders M, Jares P, Bea S, Schoenmakers E, van Krieken J, Campo E, et al. Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. Br J Haematol. 2008;143:210-21 pubmed publisher
    b>Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation and several other cytogenetic aberrations, including heterozygous loss of chromosomal arms 1p, 6q, 11q and 13q and/or gains of 3q and 8q...
  40. Salar A, Juanpere N, Bellosillo B, Domingo Domenech E, Espinet B, Seoane A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274-80 pubmed
    The frequency of gastrointestinal (GI) tract involvement in mantle cell lymphoma (MCL) at diagnosis is reported to be below 30%...
  41. Rodriguez J, Gutierrez A, Obrador Hevia A, Fernandez De Mattos S, Cabanillas F. Therapeutic concepts in mantle cell lymphoma. Eur J Haematol. 2010;85:371-86 pubmed publisher
    b>Mantle cell lymphoma has been considered an incurable disease with current chemotherapy regimens...
  42. Dreger P, Rieger M, Seyfarth B, Hensel M, Kneba M, Ho A, et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica. 2007;92:42-9 pubmed
    Autologous stem cell transplantation (ASCT) is effective in mantle cell lymphoma (MCL). We investigated whether incorporation of rituximab into the high-dose regimen might further improve the results of ASCT in patients with MCL.
  43. Chung R, Peters A, Armanious H, Anand M, Gelebart P, Lai R. Biological and clinical significance of GSK-3beta in mantle cell lymphoma--an immunohistochemical study. Int J Clin Exp Pathol. 2010;3:244-53 pubmed
    ..We recently reported that mantle cell lymphoma (MCL) frequently shows evidence of GSK-3beta inactivation, since GSK-3beta is phoshorylated at its ..
  44. Hess G, Smith S, Berkenblit A, Coiffier B. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol. 2009;36 Suppl 3:S37-45 pubmed publisher
    ..of mammalian target of rapamycin (mTOR), has anti-tumor activity in patients with relapsed or refractory mantle cell lymphoma (MCL) and other mature lymphoid neoplasms...
  45. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce M, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008;19:1327-30 pubmed publisher
    Reported median overall survival (OS) in patients with mantle cell lymphoma (MCL) has been reported to be just 3-4 years. As a consequence, first-line treatment has become more aggressive...
  46. Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23:1320-8 pubmed publisher
    b>Mantle cell lymphoma (MCL) accounts for 5-10% of all non-Hodgkin lymphomas and has the worst prognosis among all lymphomas...
  47. Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros L, et al. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. Leukemia. 2009;23:784-90 pubmed publisher
    b>Mantle cell lymphoma (MCL) is a clinically aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) and overexpression of cyclin D1...
  48. Wang M, Zhang L, Han X, Yang J, Qian J, Hong S, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood. 2007;109:5455-62 pubmed
    ..This study was undertaken to evaluate the therapeutic efficacy of atiprimod on mantle cell lymphoma (MCL) and elucidate the mechanism by which it induces cell apoptosis...
  49. Yoo S, Kim Y, Jeon Y, Kim C. CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. Pathol Res Pract. 2008;204:779-83 pubmed publisher
    ..We present a case of mantle cell lymphoma presenting as conjunctival mass...
  50. Iwuanyanwu E, Medeiros L, Romaguera J, Fayad L. Mantle cell lymphoma with a rare involvement of the testicle. Leuk Lymphoma. 2007;48:1242-3 pubmed
  51. Akyurek N, Drakos E, Giaslakiotis K, Knoblock R, Abruzzo L, Ning Y, et al. Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma. Hum Pathol. 2010;41:1448-55 pubmed publisher
    b>Mantle cell lymphoma is a distinct type of B-cell lymphoma characterized by the t(11;14)(q13;q32)...
  52. Wang M, Atayar C, Rosati S, Bosga Bouwer A, Kluin P, Visser L. JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol. 2009;218:95-103 pubmed publisher
    b>Mantle cell lymphoma (MCL) is characterized by genetic instability and a poor prognosis. Many blastoid variants are (hypo)tetraploid and have an even worse prognosis...
  53. Singh A, Evens A, Anderson R, Beckstead J, Sankar N, Sassano A, et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol. 2010;150:158-69 pubmed publisher
    b>Mantle cell lymphoma (MCL) is characterized by translocation t(11;14)(q13;q32), aggressive clinical behaviour, and poor patient outcomes following conventional chemotherapy...
  54. Wang M, Han X, Zhang L, Yang J, Qian J, Shi Y, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008;22:179-85 pubmed
    b>Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor clinical outcome. Although front therapy induces a high rate of complete remission (CR), relapse is inevitable and new regimens are much needed for relapsed MCL...
  55. Gill S, Herbert K, Prince H, Wolf M, Wirth A, Ryan G, et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol. 2009;147:83-8 pubmed publisher
    Reported rates of central nervous system (CNS) involvement in mantle cell lymphoma (MCL) are highly variable but substantial (4-26%)...
  56. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia. 2008;22:2097-105 pubmed publisher
    Cyclin D1 overexpression is the hallmark of mantle cell lymphoma (MCL). However, the importance of cyclin D1 in the maintenance and progression of the disease remains to be defined...
  57. Dal Col J, Dolcetti R. GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma. Cell Cycle. 2008;7:2813-6 pubmed
    ..This is particularly true for mantle cell lymphoma (MCL) in which cyclin D1 is overexpressed as a consequence of the t(11;14)(q13;q32) translocation...
  58. Pham L, Tamayo A, Li C, Bornmann W, Priebe W, Ford R. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther. 2010;9:2026-36 pubmed publisher
    b>Mantle cell lymphoma (MCL) is an aggressive histotype of B-cell non-Hodgkin lymphoma that has increased in incidence over the past few decades and is incurable, usually poorly responsive to standard chemotherapy combinations, and ..
  59. Prasad A, Park I, Allen H, Zhang X, Reddy M, Boominathan R, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene. 2009;28:1518-28 pubmed publisher
    b>Mantle cell lymphoma (MCL) is characterized by the uncontrolled overexpression of cyclin D1. Styryl sulfonyl compounds have shown potent antitumor activity against MCL by inducing cell-cycle arrest and apoptosis...
  60. Leonard J, Williams M, Goy A, Grant S, Pfreundschuh M, Rosen S, et al. Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma. 2009;9:267-77 pubmed publisher
    b>Mantle cell lymphoma (MCL) exhibits considerable molecular heterogeneity and complexity, and is regarded as one of the most challenging lymphomas to treat...
  61. Crysandt M, Neumann B, Das M, Engelbertz V, Bendel M, Galm O, et al. Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol. 2007;79:546-9 pubmed
    ..In mantle cell lymphoma (MCL), follicular lymphoma and diffuse large B-cell lymphoma, rituximab has been used as monotherapy and in ..
  62. Gustafsson K, Sander B, Bielawski J, Hannun Y, Flygare J. Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism. Mol Cancer Res. 2009;7:1086-98 pubmed publisher
    Ceramide levels are elevated in mantle cell lymphoma (MCL) cells following treatment with cannabinoids...
  63. Stefancikova L, Moulis M, Fabian P, Falkova I, Vasova I, Kren L, et al. Complex analysis of cyclin D1 expression in mantle cell lymphoma: two cyclin D1-negative cases detected. J Clin Pathol. 2009;62:948-50 pubmed publisher
    The cytogenetic and diagnostic hallmark of mantle cell lymphoma (MCL) is translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1. Cyclin D1 expression was analysed in 32 cases of MCL.
  64. Guggisberg K, Jordan R. Mantle cell lymphoma of the oral cavity: case series and comprehensive review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:98-104 pubmed publisher
    b>Mantle cell lymphoma (MCL) is a rare B-cell neoplasm that has only recently been defined as a distinct entity...
  65. Rasmussen P, Sjö L, Prause J, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009;93:1047-51 pubmed publisher
    To characterise clinicopathological features of mantle cell lymphoma (MCL) in the orbital and adnexal region.
  66. Hartmann E, Ott G, Rosenwald A. Molecular outcome prediction in mantle cell lymphoma. Future Oncol. 2009;5:63-73 pubmed publisher
    b>Mantle cell lymphoma (MCL), a subtype of B-cell non-Hodgkin lymphoma, is usually incurable with current therapeutic approaches and the clinical course displays considerable variability...
  67. Vater I, Wagner F, Kreuz M, Berger H, Martin Subero J, Pott C, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol. 2009;144:317-31 pubmed publisher
    The translocation t(11;14)(q13;q32) is the genetic hallmark of mantle cell lymphoma (MCL) but is not sufficient for inducing lymphomagenesis...
  68. Mozos A, Royo C, Hartmann E, de Jong D, Baro C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555-62 pubmed publisher
    Cyclin D1-negative mantle cell lymphoma is difficult to distinguish from other small B-cell lymphomas. The clinical and pathological characteristics of patients with this form of lymphoma have not been well defined...
  69. Sabnani I, Varguese J, Wascher R, Youngworth H, Tsang P. Multiple synchronous unusual extranodal sites of relapse in a patient with mantle cell lymphoma. Clin Adv Hematol Oncol. 2007;5:797-8,802; discussion 802-3 pubmed
  70. Pott C, Hoster E, Delfau Larue M, Beldjord K, Böttcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215-23 pubmed publisher
    The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial)...
  71. Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia. 2007;21:524-8 pubmed
    ..reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL)...
  72. Brennan S, Meade B, Wang Q, Merchant A, Kowalski J, Matsui W. Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood. 2010;116:4185-91 pubmed publisher
    Patients with mantle cell lymphoma (MCL) typically respond to initial treatment but subsequently relapse. This pattern suggests that a population of MCL cells is both drug resistant and capable of clonogenic growth...
  73. Dreyling M, Weigert O, Hiddemann W. Current treatment standards and future strategies in mantle cell lymphoma. Ann Oncol. 2008;19 Suppl 4:iv41-4 pubmed publisher
  74. Rolland D, Camara Clayette V, Barbarat A, Salles G, Coiffier B, Ribrag V, et al. Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. Cancer Chemother Pharmacol. 2008;61:855-63 pubmed
    The cytotoxic activity of the farnesyltranseferase inhibitor R115777 was evaluated in cell lines representative of mantle cell lymphoma (MCL).
  75. Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706-14 pubmed
    ..has been shown to improve response rates and progression-free survival in patients with indolent or mantle cell lymphoma. However, the impact of R-chemo on overall survival is unclear...
  76. Meral M, Demirpence M, Gonen C, Akarsu M, Kayahan H, Demirkan F, et al. Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol. 2008;19:117-20 pubmed
    ..The most frequent endoscopic finding of mantle cell lymphoma is multiple lymphomatous polyposis, which is a very rare entity...
  77. Inwards D, Fishkin P, Hillman D, Brown D, Ansell S, Kurtin P, et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer. 2008;113:108-16 pubmed publisher
    The objective of this study was to test cladribine (2-CDA) alone and in combination with rituximab in patients with mantle cell lymphoma (MCL).
  78. Perez Galan P, Roué G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007;109:4441-9 pubmed
    b>Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma resistant to conventional chemotherapy. The Bcl-2 pathway is deregulated in these tumors and may represent an interesting target for new therapeutic strategies...
  79. Sztarkier I, Levy I, Walfisch S, Delgado J, Benharroch D. Mantle cell lymphoma in a tubular adenoma: unusual presentation with synchronous colonic carcinoma. Ann Diagn Pathol. 2009;13:47-9 pubmed publisher
    ..A bone marrow biopsy showed malignant lymphoma, suggestive of mantle cell lymphoma (MCL). Colonoscopy at this time revealed 3 colonic tubular adenomas...
  80. Younes A. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers. Autophagy. 2008;4:707-9 pubmed
    ..target of rapamycin (mTOR) has recently demonstrated a 30% to 40% response rate in patients with relapsed mantle cell lymphoma (MCL)...
  81. Brizova H, Kalinova M, Krskova L, Mrhalova M, Kodet R. Quantitative measurement of cyclin D1 mRNA, a potent diagnostic tool to separate mantle cell lymphoma from other B-cell lymphoproliferative disorders. Diagn Mol Pathol. 2008;17:39-50 pubmed publisher
    Cyclin D1 overexpression as a result of t(11;14) is a specific marker for diagnosis of mantle cell lymphoma (MCL) and plays an important role in MCL pathogenesis...
  82. Palumbo G, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33:1212-6 pubmed publisher
    Chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL) share many features and their differential diagnosis may be challenging, especially when a leukemic picture alone is present...
  83. Varghese A, Sayala H, Evans P, O Connor S, Patmore R, Hillmen P, et al. Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma. Leuk Lymphoma. 2008;49:1618-9 pubmed publisher
  84. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142:149-65 pubmed publisher
    b>Mantle cell lymphoma (MCL) is a well-defined lymphoid neoplasm characterized by a proliferation of mature B lymphocytes expressing CD5 that may show a spectrum of morphological and phenotypic features broader than initially described...